Hayley A. McQuilten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hayley A. McQuilten has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Kedzierska
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia
13 shared publications - Lukasz Kedzierski
Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
8 shared publications - Thi Hoang Oanh Nguyen
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia
8 shared publications - Stephen John Kent
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
7 shared publications - Adam Kenneth Wheatley
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
6 shared publications - Amy W. Chung
Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
6 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Atypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity
Indigenous people are disproportionately impacted by influenza viruses and chronic multimorbidity. Yet, the impact of comorbidities on immunity towards influenza vaccination is unknown. We recruited Australian First Nations and non-Indigenous people vaccinated with seasonal inactivated influenza vaccines and assessed their humoral and cellular responses in the context of comorbidities at baseline and after immunisation. Our study highlights prevalence of multimorbidity in First Nations people, associated with elevated baseline cellular activation, pro-inflammatory cytokines and agalactosylated IgG. Following vaccination, all groups had increased antibody titres and haemagglutinin-specific IgD - B-cell frequencies as compared to baseline. However, we reveal increased prevalence of pro-inflammatory atypical B cells within influenza haemagglutinin-specific IgD - B cells and lack of significant circulating T follicular helper type-1 cell activation in individuals with comorbidities, correlating with multimorbidity-associated baseline inflammatory features. Our findings thus reveal that vaccinees with comorbidities, both Australian First Nations and non-Indigenous participants, can mount antibody responses following influenza vaccination, although their cellular immune features, haemagglutinin-specific IgD - B cells and cT FH 1 compartments, display features of perturbed humoral axis functionality linked to multimorbidity-associated inflammation and IgG glycosylation patterns at baseline. Our study supports influenza vaccination for individuals with comorbidities, especially relevant to Indigenous populations with prevalent multimorbidity.
- 5 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAtypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity
Indigenous people are disproportionately impacted by influenza viruses and chronic multimorbidity. Yet, the impact of comorbidities on immunity towards influenza vaccination is unknown. We recruited Australian First Nations and non-Indigenous people vaccinated with seasonal inactivated influenza vaccines and assessed their humoral and cellular responses in the context of comorbidities at baseline and after immunisation. Our study highlights prevalence of multimorbidity in First Nations people, associated with elevated baseline cellular activation, pro-inflammatory cytokines and agalactosylated IgG. Following vaccination, all groups had increased antibody titres and haemagglutinin-specific IgD - B-cell frequencies as compared to baseline. However, we reveal increased prevalence of pro-inflammatory atypical B cells within influenza haemagglutinin-specific IgD - B cells and lack of significant circulating T follicular helper type-1 cell activation in individuals with comorbidities, correlating with multimorbidity-associated baseline inflammatory features. Our findings thus reveal that vaccinees with comorbidities, both Australian First Nations and non-Indigenous participants, can mount antibody responses following influenza vaccination, although their cellular immune features, haemagglutinin-specific IgD - B cells and cT FH 1 compartments, display features of perturbed humoral axis functionality linked to multimorbidity-associated inflammation and IgG glycosylation patterns at baseline. Our study supports influenza vaccination for individuals with comorbidities, especially relevant to Indigenous populations with prevalent multimorbidity.
- 1 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (843) , eaea8621
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses
Vaccination is the best way to combat annual influenza epidemics, yet the breadth of vaccine-induced humoral immunity toward decades of future differentially evolving influenza A (IAV) and influenza B (IBV) viruses is unclear. Using historic 1994 influenza vaccination cohorts of young and older adults, we defined antibody responses elicited by 1994 vaccination against future influenza strains spanning three decades of differentially evolving IAV and IBV strains. Quality of antibody responses and vaccine-induced and cross-reactive B cell memory responses were investigated. Vaccination increased antibody titers against all 1994 vaccine components in younger and older adults. Antibodies to future H1N1 strains were also detected across younger and older adults, including nonneutralizing hemagglutinin (HA) stem responses. Prominent boosting against earlier B/Yamagata/16/1988 and future Yamagata lineage strains was also observed, but antibody responses toward future rapidly evolving H3N2 strains were minimal. Systems serology revealed divergent antibody signatures between younger and older adults against future antigens. However, postvaccination responses were of high quality in both age groups. Cross-reactive HA-specific memory B cells induced by 1994 vaccination bound to vaccine and future H1 and IBV strains but exhibited minimal responses against H3. Group 1 cross-reactive H1/H5 stalk–specific responses also contributed to the overall H1 future response, whereas cross-reactive H3/H7 stalk–specific B cells were not detected. Our study provides insights into the breadth of vaccine-induced humoral immunity toward future influenza viruses over 30 years of influenza virus evolution, including newly emerging pandemic strains, and highlights the unmet need to optimize future vaccines strategies, especially for H3N2.
- 1 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (843) , eaea8621
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses
Vaccination is the best way to combat annual influenza epidemics, yet the breadth of vaccine-induced humoral immunity toward decades of future differentially evolving influenza A (IAV) and influenza B (IBV) viruses is unclear. Using historic 1994 influenza vaccination cohorts of young and older adults, we defined antibody responses elicited by 1994 vaccination against future influenza strains spanning three decades of differentially evolving IAV and IBV strains. Quality of antibody responses and vaccine-induced and cross-reactive B cell memory responses were investigated. Vaccination increased antibody titers against all 1994 vaccine components in younger and older adults. Antibodies to future H1N1 strains were also detected across younger and older adults, including nonneutralizing hemagglutinin (HA) stem responses. Prominent boosting against earlier B/Yamagata/16/1988 and future Yamagata lineage strains was also observed, but antibody responses toward future rapidly evolving H3N2 strains were minimal. Systems serology revealed divergent antibody signatures between younger and older adults against future antigens. However, postvaccination responses were of high quality in both age groups. Cross-reactive HA-specific memory B cells induced by 1994 vaccination bound to vaccine and future H1 and IBV strains but exhibited minimal responses against H3. Group 1 cross-reactive H1/H5 stalk–specific responses also contributed to the overall H1 future response, whereas cross-reactive H3/H7 stalk–specific B cells were not detected. Our study provides insights into the breadth of vaccine-induced humoral immunity toward future influenza viruses over 30 years of influenza virus evolution, including newly emerging pandemic strains, and highlights the unmet need to optimize future vaccines strategies, especially for H3N2.
- Open Access
- 9 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1456-1477
IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination
Influenza viruses continue to cause a substantial global disease burden. Despite influenza vaccination, some individuals succumb to life-threatening influenza or death. Yet our understanding of immune features elicited by vaccination and influenza A and B virus (IAV, IBV) infection is limited. To define molecular signatures of influenza-specific B-cells, we performed scRNA-sequencing of influenza-specific B-cells in vaccinees and hospitalized IAV/IBV-infected patients using HA-probes. We observed increased interferon-stimulated gene signatures ( IF44L , IFITM1 and XAF1 ), in total B-cells from IBV-patients, but not at 1-month following patients’ recovery or in IAV-patients or vaccinees. Phenotypic differentiation and isotype class-switching of HA-specific B-cells were observed following vaccination, with clonal sharing between memory and atypical B-cell phenotypes. In-vitro influenza virus infection experiments showed IBVs having higher infectivity of human PBMCs, including B-cells, and reduced B-cell proliferation compared to IAV, potentially associated with antiproliferative effect of IFITM1. We provide key insights into B-cell immunity towards IBV and IAV infections and vaccination, which will inform rational vaccine design and therapeutic strategies aimed at eliciting robust HA-specific B-cell responses, while minimizing adverse effects caused by natural infection.
- 9 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1456-1477
Open AccessIFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination
Influenza viruses continue to cause a substantial global disease burden. Despite influenza vaccination, some individuals succumb to life-threatening influenza or death. Yet our understanding of immune features elicited by vaccination and influenza A and B virus (IAV, IBV) infection is limited. To define molecular signatures of influenza-specific B-cells, we performed scRNA-sequencing of influenza-specific B-cells in vaccinees and hospitalized IAV/IBV-infected patients using HA-probes. We observed increased interferon-stimulated gene signatures ( IF44L , IFITM1 and XAF1 ), in total B-cells from IBV-patients, but not at 1-month following patients’ recovery or in IAV-patients or vaccinees. Phenotypic differentiation and isotype class-switching of HA-specific B-cells were observed following vaccination, with clonal sharing between memory and atypical B-cell phenotypes. In-vitro influenza virus infection experiments showed IBVs having higher infectivity of human PBMCs, including B-cells, and reduced B-cell proliferation compared to IAV, potentially associated with antiproliferative effect of IFITM1. We provide key insights into B-cell immunity towards IBV and IAV infections and vaccination, which will inform rational vaccine design and therapeutic strategies aimed at eliciting robust HA-specific B-cell responses, while minimizing adverse effects caused by natural infection.
- Open Access
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10344
High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures
Hyperactivated immunity underpins severe outcomes of respiratory viral infections, yet specific immune perturbations are ill-defined. Our recent findings identified OLAH (oleoyl-ACP-hydrolase) as a driver of life-threatening viral diseases. In the same patient cohorts, we now identify the gene encoding IL-18Rα chain ( IL18R1 ), as being highly expressed in life-threatening influenza, COVID-19, RSV and multisystem inflammatory syndrome in children (MIS-C) and demonstrate markedly elevated surface protein IL-18Rα expression on CD8 T cells in these infections. Using a mouse model of severe influenza, we further show that high IL-18Rα expression on effector T cells is associated with increased disease severity. We find that IL-18Rα expression on CD8 T cells is inversely associated with cytotoxicity-related genes, including granzyme A, granzyme B, perforin, Eomes, and KLRG-1. Our study demonstrates that IL-18Rα is associated with severe and fatal respiratory disease outcomes and proposes the use of IL-18Rα as a potential biomarker for severe respiratory viral disease.
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10344
Open AccessHigh expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures
Hyperactivated immunity underpins severe outcomes of respiratory viral infections, yet specific immune perturbations are ill-defined. Our recent findings identified OLAH (oleoyl-ACP-hydrolase) as a driver of life-threatening viral diseases. In the same patient cohorts, we now identify the gene encoding IL-18Rα chain ( IL18R1 ), as being highly expressed in life-threatening influenza, COVID-19, RSV and multisystem inflammatory syndrome in children (MIS-C) and demonstrate markedly elevated surface protein IL-18Rα expression on CD8 T cells in these infections. Using a mouse model of severe influenza, we further show that high IL-18Rα expression on effector T cells is associated with increased disease severity. We find that IL-18Rα expression on CD8 T cells is inversely associated with cytotoxicity-related genes, including granzyme A, granzyme B, perforin, Eomes, and KLRG-1. Our study demonstrates that IL-18Rα is associated with severe and fatal respiratory disease outcomes and proposes the use of IL-18Rα as a potential biomarker for severe respiratory viral disease.
- Open Access
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (5)
Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population
Background: Immunosenescence increases the susceptibility to viral respiratory infections, but its effects on nasopharyngeal innate immunity, a critical determinant of response to viral infection, are not well understood. INNA-051 is a Toll-like receptor (TLR)2/6 agonist that activates innate immune pathways associated with antiviral host defence in younger individuals (aged 19–53 years), and in pre-clinical models protects against diverse viruses. Here we assessed INNA-051 in older adults, measuring host defence indicators, and tested its ability to protect aged mice from influenza. Methods: Clinical safety, tolerability and elicitation of host defence biomarkers by 300 μg of intranasal INNA-051 were assessed in a cohort of 12 healthy older volunteers (aged 66–80 years) included in a recently reported randomised placebo-controlled, dose escalation phase 1 study. Aged mice (64 weeks) received repeated intranasal doses of INNA-051 on days −4 and −1 prior to infection with influenza (H3N2 Udorn, 500 PFU) and response was assessed on day 4 post-infection. Results: In humans INNA-051 was well tolerated and significantly increased innate immunity host defence pathways within 8 h after each dose. In aged mice, nose-only dosing of INNA-051 stimulated innate nasopharyngeal innate immunity, primed adaptive immunity and effectively reduced lung influenza viral load. Conclusions: INNA-051 induced innate immune priming in older individuals and attenuated influenza infection in aged mice. TLR2/6 agonist-mediated responses remain functional in older individuals and this study supports further clinical investigation in aged populations known to be susceptible to viral respiratory infections.
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (5)
Open AccessPriming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population
Background: Immunosenescence increases the susceptibility to viral respiratory infections, but its effects on nasopharyngeal innate immunity, a critical determinant of response to viral infection, are not well understood. INNA-051 is a Toll-like receptor (TLR)2/6 agonist that activates innate immune pathways associated with antiviral host defence in younger individuals (aged 19–53 years), and in pre-clinical models protects against diverse viruses. Here we assessed INNA-051 in older adults, measuring host defence indicators, and tested its ability to protect aged mice from influenza. Methods: Clinical safety, tolerability and elicitation of host defence biomarkers by 300 μg of intranasal INNA-051 were assessed in a cohort of 12 healthy older volunteers (aged 66–80 years) included in a recently reported randomised placebo-controlled, dose escalation phase 1 study. Aged mice (64 weeks) received repeated intranasal doses of INNA-051 on days −4 and −1 prior to infection with influenza (H3N2 Udorn, 500 PFU) and response was assessed on day 4 post-infection. Results: In humans INNA-051 was well tolerated and significantly increased innate immunity host defence pathways within 8 h after each dose. In aged mice, nose-only dosing of INNA-051 stimulated innate nasopharyngeal innate immunity, primed adaptive immunity and effectively reduced lung influenza viral load. Conclusions: INNA-051 induced innate immune priming in older individuals and attenuated influenza infection in aged mice. TLR2/6 agonist-mediated responses remain functional in older individuals and this study supports further clinical investigation in aged populations known to be susceptible to viral respiratory infections.
- Open Access
- 13 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Evaluation of Intranasal TLR2/6 agonist INNA-051: Safety, Tolerability and Proof of Pharmacology
Background: Local priming of the innate immune system with a TLR2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases.Objectives: To understand the potential of prophylactic treatment with a TLR2/6 agonist as an enhancer of innate immunity pathways leading to accelerated respiratory virus clearance from the upper airways.Methods: Two randomized, double-blind, placebo-controlled clinical trials were conducted in healthy adult participants. The first dose-escalation study assessed safety, tolerability and mechanistic biomarkers following single and repeated intranasal administrations of INNA-051. The second was an Influenza A viral challenge study assessing the impact of treatment on host defence biomarkers and viral load.Results: INNA-051 was well tolerated in both studies, with no dose-limiting toxicities identified. Mechanistic biomarkers assessed in both studies demonstrated the expected engagement of pharmacology, including innate immune pathways. There were lower than anticipated rates of infection. Post hoc analysis conducted in laboratory-confirmed infected participants with low or no antibody titre against the challenge virus showed INNA-051 treatment led to significantly shorter duration of infection and increased expression of genes and pathways associated with host defence responses against influenza.Conclusions: The safety and pharmacology profile of INNA-051 confirms preclinical studies. INNA-051 increased expression of genes and pathways associated with host defence responses against influenza and was associated with shorter duration of infection. These studies support further clinical assessment in the context of natural viral respiratory tract infections in individuals at increased risk of severe illness.
- 13 June 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (6)
Open AccessEvaluation of Intranasal TLR2/6 agonist INNA-051: Safety, Tolerability and Proof of Pharmacology
Background: Local priming of the innate immune system with a TLR2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases.Objectives: To understand the potential of prophylactic treatment with a TLR2/6 agonist as an enhancer of innate immunity pathways leading to accelerated respiratory virus clearance from the upper airways.Methods: Two randomized, double-blind, placebo-controlled clinical trials were conducted in healthy adult participants. The first dose-escalation study assessed safety, tolerability and mechanistic biomarkers following single and repeated intranasal administrations of INNA-051. The second was an Influenza A viral challenge study assessing the impact of treatment on host defence biomarkers and viral load.Results: INNA-051 was well tolerated in both studies, with no dose-limiting toxicities identified. Mechanistic biomarkers assessed in both studies demonstrated the expected engagement of pharmacology, including innate immune pathways. There were lower than anticipated rates of infection. Post hoc analysis conducted in laboratory-confirmed infected participants with low or no antibody titre against the challenge virus showed INNA-051 treatment led to significantly shorter duration of infection and increased expression of genes and pathways associated with host defence responses against influenza.Conclusions: The safety and pharmacology profile of INNA-051 confirms preclinical studies. INNA-051 increased expression of genes and pathways associated with host defence responses against influenza and was associated with shorter duration of infection. These studies support further clinical assessment in the context of natural viral respiratory tract infections in individuals at increased risk of severe illness.
- Open Access
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age
Influenza B viruses (IBVs) cause substantive morbidity and mortality, and yet immunity towards IBVs remains understudied. CD8+ T-cells provide broadly cross-reactive immunity and alleviate disease severity by recognizing conserved epitopes. Despite the IBV burden, only 18 IBV-specific T-cell epitopes restricted by 5 HLAs have been identified currently. A broader array of conserved IBV T-cell epitopes is needed to develop effective cross-reactive T-cell based IBV vaccines. Here we identify 9 highly conserved IBV CD8+ T-cell epitopes restricted to HLA-B*07:02, HLA-B*08:01 and HLA-B*35:01. Memory IBV-specific tetramer+CD8+ T-cells are present within blood and tissues. Frequencies of IBV-specific CD8+ T-cells decline with age, but maintain a central memory phenotype. HLA-B*07:02 and HLA-B*08:01-restricted NP30-38 epitope-specific T-cells have distinct T-cell receptor repertoires. We provide structural basis for the IBV HLA-B*07:02-restricted NS1196-206 (11-mer) and HLA-B*07:02-restricted NP30-38 epitope presentation. Our study increases the number of IBV CD8+ T-cell epitopes, and defines IBV-specific CD8+ T-cells at cellular and molecular levels, across tissues and age.
- 29 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
Open AccessCD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age
Influenza B viruses (IBVs) cause substantive morbidity and mortality, and yet immunity towards IBVs remains understudied. CD8+ T-cells provide broadly cross-reactive immunity and alleviate disease severity by recognizing conserved epitopes. Despite the IBV burden, only 18 IBV-specific T-cell epitopes restricted by 5 HLAs have been identified currently. A broader array of conserved IBV T-cell epitopes is needed to develop effective cross-reactive T-cell based IBV vaccines. Here we identify 9 highly conserved IBV CD8+ T-cell epitopes restricted to HLA-B*07:02, HLA-B*08:01 and HLA-B*35:01. Memory IBV-specific tetramer+CD8+ T-cells are present within blood and tissues. Frequencies of IBV-specific CD8+ T-cells decline with age, but maintain a central memory phenotype. HLA-B*07:02 and HLA-B*08:01-restricted NP30-38 epitope-specific T-cells have distinct T-cell receptor repertoires. We provide structural basis for the IBV HLA-B*07:02-restricted NS1196-206 (11-mer) and HLA-B*07:02-restricted NP30-38 epitope presentation. Our study increases the number of IBV CD8+ T-cell epitopes, and defines IBV-specific CD8+ T-cells at cellular and molecular levels, across tissues and age.
- Open Access
- 23 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Prior infection with unrelated neurotropic virus exacerbates influenza disease and impairs lung T cell responses
Immunity to infectious diseases is predominantly studied by measuring immune responses towards a single pathogen, although co-infections are common. In-depth mechanisms on how co-infections impact anti-viral immunity are lacking, but are highly relevant to treatment and prevention. We established a mouse model of co-infection with unrelated viruses, influenza A (IAV) and Semliki Forest virus (SFV), causing disease in different organ systems. SFV infection eight days before IAV infection results in prolonged IAV replication, elevated cytokine/chemokine levels and exacerbated lung pathology. This is associated with impaired lung IAV-specific CD8+ T cell responses, stemming from suboptimal CD8+ T cell activation and proliferation in draining lymph nodes, and dendritic cell paralysis. Prior SFV infection leads to increased blood brain barrier permeability and presence of IAV RNA in brain, associated with increased trafficking of IAV-specific CD8+ T cells and establishment of long-term tissue-resident memory. Relative to lung IAV-specific CD8+ T cells, brain memory IAV-specific CD8+ T cells have increased TCR repertoire diversity within immunodominant DbNP366+CD8+ and DbPA224+CD8+ responses, featuring suboptimal TCR clonotypes. Overall, our study demonstrates that infection with an unrelated neurotropic virus perturbs IAV-specific immune responses and exacerbates IAV disease. Our work provides key insights into therapy and vaccine regimens directed against unrelated pathogens.
- 23 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessPrior infection with unrelated neurotropic virus exacerbates influenza disease and impairs lung T cell responses
Immunity to infectious diseases is predominantly studied by measuring immune responses towards a single pathogen, although co-infections are common. In-depth mechanisms on how co-infections impact anti-viral immunity are lacking, but are highly relevant to treatment and prevention. We established a mouse model of co-infection with unrelated viruses, influenza A (IAV) and Semliki Forest virus (SFV), causing disease in different organ systems. SFV infection eight days before IAV infection results in prolonged IAV replication, elevated cytokine/chemokine levels and exacerbated lung pathology. This is associated with impaired lung IAV-specific CD8+ T cell responses, stemming from suboptimal CD8+ T cell activation and proliferation in draining lymph nodes, and dendritic cell paralysis. Prior SFV infection leads to increased blood brain barrier permeability and presence of IAV RNA in brain, associated with increased trafficking of IAV-specific CD8+ T cells and establishment of long-term tissue-resident memory. Relative to lung IAV-specific CD8+ T cells, brain memory IAV-specific CD8+ T cells have increased TCR repertoire diversity within immunodominant DbNP366+CD8+ and DbPA224+CD8+ responses, featuring suboptimal TCR clonotypes. Overall, our study demonstrates that infection with an unrelated neurotropic virus perturbs IAV-specific immune responses and exacerbates IAV disease. Our work provides key insights into therapy and vaccine regimens directed against unrelated pathogens.
- Open Access
- 27 November 2023
- Published by Elsevier in EBioMedicine
- Vol. 98, 104878
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
- 27 November 2023
- Published by Elsevier in EBioMedicine
- Vol. 98, 104878
Open AccessInterim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
- Open Access
- 25 September 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (11) , 1890-1907
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8+ T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M158–66 (A2/M158) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older adults closely resemble those of newborns and children, despite being clonally distinct. Only child-derived and adult-derived A2/M158+CD8+ T cells had the potential to differentiate into highly cytotoxic epitope-specific CD8+ T cells, which was linked to highly functional public T cell receptor (TCR)αβ signatures. Suboptimal TCRαβ signatures in older adults led to less proliferation, polyfunctionality, avidity and recognition of peptide mutants, although displayed no signs of exhaustion. These data suggest that priming T cells at different stages of life might greatly affect CD8+ T cell responses toward viral infections.
- 25 September 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (11) , 1890-1907
Open AccessNewborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8+ T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M158–66 (A2/M158) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older adults closely resemble those of newborns and children, despite being clonally distinct. Only child-derived and adult-derived A2/M158+CD8+ T cells had the potential to differentiate into highly cytotoxic epitope-specific CD8+ T cells, which was linked to highly functional public T cell receptor (TCR)αβ signatures. Suboptimal TCRαβ signatures in older adults led to less proliferation, polyfunctionality, avidity and recognition of peptide mutants, although displayed no signs of exhaustion. These data suggest that priming T cells at different stages of life might greatly affect CD8+ T cell responses toward viral infections.